Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Cash Flow

v3.3.1.900
Consolidated Statement of Cash Flow - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Cash flows from operating activities    
Net loss for the period $ (9,311,913) $ (3,127,167)
Adjustments to reconcile net loss to net cash used in operating activities:    
Accrued interest and dividends on marketable securities $ 4,199 (18,473)
Decrease in reserve for inventory obsolescence (3,061)
Depreciation and amortization $ 299,995 $ 349,398
Impairment of non-current assets 466,476
Allowance for doubtful accounts 2,163,609
Gain from other non-operating activities (6,010) $ (4,669)
Non-cash share based compensation - options 52,356 549,600
Non-cash share based payments for services - shares issued 344,656 196,800
Changes in assets and liabilities    
(Increase)/decrease in trade receivables 513,583 (1,899,886)
(Increase)/decrease in notes receivables - related party 176,157 (266,378)
Increase in other receivables (54,142) (37,497)
(Increase)/decrease in inventories (226,538) 123,049
(Increase)/decrease in other assets (76,774) 56,257
Increase in trade and other payables $ 827,601 538,017
Decrease in other payables - related party (6,586)
Decrease in deferred revenue - related party $ (305,556) (333,333)
Net cash used in operating activities (5,132,301) (3,883,929)
Cash flows from investing activities    
Purchases of property, plant and equipment (112,951) (24,988)
Purchases of marketable securities (60,940) $ (12,551,106)
Investment in Hainan Savy Akers Biosciences, Ltd. joint venture (64,091)
Proceeds from demutualization of insurance carrier 6,010 $ 4,669
Proceeds from sale of marketable securities 5,310,491 3,284,494
Net cash provided by/(used in) investing activities $ 5,078,519 (9,286,931)
Cash flows from financing activities    
Payment of short-term note payable - related party (307,500)
Proceeds from issuance of common shares 745,024
Net proceeds from issuance of common stock in initial public offering 13,101,336
Dividend distribution on Series A Convertible Preferred Stock (15,793)
Net cash provided by financing activities 13,523,067
Net increase/(decrease) in cash $ (53,782) 352,207
Cash at beginning of year 455,841 103,634
Cash at end of year 402,059 455,841
Supplemental Schedule of Non-Cash Financing and Investing Activities    
Unrealized gains/(losses) on marketable securities $ 13,893 (20,124)
Conversion of trade receivable as of December 31, 2013 to a note receivable in the year ended December 31, 2014 $ 1,209,388
Issuance of restricted common share grants to directors and officers accrued in 2014 $ 697,300